Syngene International: Peter Bains returns as CEO, Jonathan Hunt steps down
Bangalore: Syngene International Limited has announced that Jonathan Hunt has stepped down from his role as MD & CEO as well as from the Board of Directors to pursue other opportunities in due course.
Consequent to this, the Board has appointed Peter Bains as the CEO Designate of Syngene. Both changes are effective immediately, i.e., February 10, 2025.
Commenting on the announcement, Kiran Mazumdar-Shaw, Non-Executive Chairperson, Syngene International, said, “After almost 10 years with Syngene International as MD & CEO, Jonathan Hunt will be leaving to pursue other opportunities. The Board thanks Jonathan for his many contributions to the growth of the Syngene business since April 2016 and its impressive value enhancement over the last decade and wishes him well in his future endeavours.”
Read also: Syngene concludes acquisition of biologics manufacturing facility from Stelis Biopharma
Peter Bains has over three decades of experience in the biotech and pharmaceutical industry. Peter also served as CEO of Syngene from June 2010 to March 2016 and was instrumental in creating a strong foundation for the business and taking it public in 2015. Peter's deep domain experience, knowledge, and familiarity with the business, together with his leadership acumen makes him eminently qualified to step into this role.
Medical Dialogues team had earlier reported that Biocon had sold Eighty Lacs equity shares of Syngene International for Rs. 686 crores. The transacted value was the gross amount on the exchange and was subject to statutory levies, brokerage etc.
Read also: Biocon sells 80 lacs equity shares of Syngene International for Rs 686 crores
Syngene International Ltd. is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. With 2.2 Mn sq. ft of specialized discovery, development, and manufacturing facilities, Syngene works with biotech companies pursuing leading-edge science as well as multinationals, including BMS, GSK, Zoetis and Merck KGaA.
